SAN DIEGO, Dec. 8, 2010 /PRNewswire/ — Prometheus Laboratories
Inc., a specialty pharmaceutical and diagnostic company, announced
today the execution of an oncology-focused mutational analysis
services agreement with Bayer Schering Pharma AG, Germany, a
worldwide leading pharmaceutical company. The addition of this
mutational analysis services agreement broadens Bayer’s
oncology-focused molecular and pathway activation profiling
collaboration with Prometheus to include comprehensive mutational
analyses. The expanded information derived from this
agreement has the potential to improve patient stratification in
clinical studies and accelerate the development of novel oncology
diagnostic and therapeutic products.
Under the terms of this agreement, Bayer will provide clinical
samples, sourced from clinical studies, and Prometheus will perform
mutational analyses that characterize the presence or absence of
existing and novel cancer-relevant mutations in these samples.
Prometheus will be compensated based on the number and complexity
of mutational analyses it completes for Bayer.
“This agreement represents further validation of the importance
of our oncology focused CEER and mutational analysis platforms,”
said Joseph M. Limber, President and Chief Executive Officer of
Prometheus. “The combination of our mutational analysis and CEER
platforms that this agreement represents is an important step to
providing a more comprehensive analysis to Bayer, that may result
in improved selection of patients who will benefit the most from
specific drug candidates Bayer is developing. We believe this
collaboration has the potential to ultimately result in improved
outcomes for patients.”
Prometheus and Bayer entered into a research collaboration and
license agreement in March of this year. This collaboration
partners Prometheus’ proprietary oncology diagnostic CEER platform
with Bayer’s broad oncology pipeline with the objective of
stratifying patients to
‘/>”/>
